71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Journal article

Peer reviewed

V.S. Sukhin, T.J. Herzog, L. Gilbert, A. Koliadi, C. Mathews, S.E. Gill, G. Ronzino, I. Podzielinski, S. Kommoss, M. Edelson, …

ESMO open, Vol.11, p.108097

07/2026

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2026.108097View

Published (Version of record) Open

1 Record Views

Title: 71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Creators: V.S. Sukhin - National Academy of Medical Sciences of Ukraine
T.J. Herzog - University of Cincinnati Medical Center
L. Gilbert - McGill University Health Centre
A. Koliadi - Nordic Society of Gynecologic Oncology
C. Mathews - Women & Infants Hospital of Rhode Island
S.E. Gill - St. Joseph’s Candler Hospital
G. Ronzino - Ospedale Vito Fazzi
I. Podzielinski - Parkview Health
S. Kommoss - München Klinik Schwabing
M. Edelson - Gynecologic Oncology Group
B.J. Monk - Florida Cancer Specialists & Research Institute
et al.
Publication Details: ESMO open, Vol.11, p.108097
Publisher: Elsevier Ltd
Identifiers: 991006292257302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article